| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Strontium Ranelate (S-12911; Distrontium renelate; Protelos or Protos) is an approved antiosteoporotic drug in EU, it can also slow the course of osteoarthritis of the knee by both increasing bone formation and reducing bone resorption, leading to a rebalance of bone turnover in favor of bone formation. Strontium Ranelate is a strontium(II) salt of ranelic acid that, in non-skeletal cells, activates the calcium-sensing receptor (CaSR). The medication is unique in that it decreases osteoclast bone resorption while simultaneously increasing osteoblasts' production of new bone. As a result, it is advertised as a "dual action bone agent" (DABA). The treatment of severe osteoporosis in postmenopausal women who are at high risk of fracture is currently the only indication for its use.
| Targets |
Calcium channel ( IC50 = 0.5 mM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Cell Assay |
In murine marrow stromal cells, strontium ranelate has been shown to elevate prostaglandin E2 production and alkaline phosphatase activity in a manner that is dependent on COX-2.
|
||
| Animal Protocol |
|
||
| References |
|
| Molecular Formula |
C12H6N2O8SSR2
|
|
|---|---|---|
| Molecular Weight |
513.49
|
|
| Exact Mass |
513.8
|
|
| Elemental Analysis |
C, 28.07; H, 1.18; N, 5.46; O, 24.93; S, 6.24; Sr, 34.13
|
|
| CAS # |
135459-87-9
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C(C1=C(SC(=C1C#N)N(CC(=O)[O-])CC(=O)[O-])C(=O)[O-])C(=O)[O-].[Sr+2].[Sr+2]
|
|
| InChi Key |
XXUZFRDUEGQHOV-UHFFFAOYSA-J
|
|
| InChi Code |
InChI=1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4
|
|
| Chemical Name |
distrontium;5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate
|
|
| Synonyms |
S 1291-1; S-1291-1; S1291-1; S-12911; S12911; S 12911; Strontium Ranelate; trade mane: Protelos or Proto
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9475 mL | 9.7373 mL | 19.4746 mL | |
| 5 mM | 0.3895 mL | 1.9475 mL | 3.8949 mL | |
| 10 mM | 0.1947 mL | 0.9737 mL | 1.9475 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05712616 | Recruiting | Drug: Strontium Ranelate Drug: Lacto-N-Hexaose |
Fragility Fracture Clinical Trial |
Aga Khan University Hospital, Pakistan |
November 1, 2021 | Phase 4 |
| NCT03937518 | Completed | Drug: Strontium Ranelate Other: physiotherapy |
Knee Osteoarthritis | Mansoura University | July 1, 2018 | Not Applicable |
| NCT01544894 | Completed | Drug: Raloxifene Drug: Strontium ranelate |
Compliance Postmenopausal Osteoporosis |
University of Valencia | September 2009 | Phase 4 |
| NCT00239629 | Completed | Drug: Teriparatide Drug:Strontium ranelate |
Postmenopausal Osteoporosis | Eli Lilly and Company | September 2005 | Phase 4 |
| NCT01222026 | Completed | Drug: Placebo Drug: Strontium Ranelate + Ca/Vitamin-D |
Osteopenia Osteoporosis |
Medical University of Vienna | September 2010 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
